Prediction of tumor radiosensitivity by hexafluoromisonidazole retention monitored by [1H]/[19F] magnetic resonance spectroscopy.
Hexafluoromisonidazole (CCI-103F) is a hypoxic cell label that can be measured by in vivo [1H]/[19F] magnetic resonance spectroscopy (MRS). The retention of CCI-103F in SCCVII tumors was found to be correlated with tumor size, with larger tumors retaining more label. Such a correlation was anticipated, as larger SCCVII tumors have larger hypoxic fractions. A significant but less strong correlation was also found between CCI-103F retention and the fraction of tumor cells surviving after 10 Gy irradiation, with tumors that retained larger amounts of CCI-103F having higher surviving fractions. These results indicated that non-invasive MRS measurement of CCI-103F retention could predict radiosensitivity in SCCVII tumors. The lack of a strong correlation between CCI-103F retention and radiosensitivity, however, indicated that hypoxic fraction was not the only factor influencing radiosensitivity in these tumors.
Li
S J
SJ
Department of Radiology, Medical College of Wisconsin, Milwaukee 53226.
Jin
G Y
GY
Moulder
J E
JE
D000818:Animals; D015687:Cell Hypoxia; D002470:Cell Survival / Q000528:radiation effects; D005720:Gamma Rays; D009682:Magnetic Resonance Spectroscopy; D051379:Mice; D008809:Mice, Inbred C3H; D009374:Neoplasms, Experimental / Q000000981:diagnostic imaging*; D009593:Nitroimidazoles; D011836:Radiation Tolerance; D011859:Radiography; D011877:Radionuclide Imaging; D014407:Tumor Cells, Cultured; D005466:Fluorocarbons
D009593:Nitroimidazoles; C049948:CCI 103F; D005466:Fluorocarbons